Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) dropped 7.6% on Monday . Finally, Sanford C. Bernstein assumed coverage on Avidity Biosciences in a report on Tuesday, June 24th. Osaic Holdings Inc. lifted its stake in shares of Avidity Biosciences by 1,659.1% in the 2nd quarter. Avidity Biosciences Company Profile(Get Free Report)Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. Further ReadingReceive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.